Eur Heart J:缺血性心脏T细胞反应的表型研究

2019-12-31 不详 MedSci原创

心肌梗死引起的持续性心脏T细胞反应与随后的不良心室重塑和心力衰竭进展有关,目前尚无T细胞受体(TCR)剧集的变化与缺血心力衰竭心脏T细胞表型特征结合的数据。通过高通量测序对TCR基因序列的分析发现,与对照心脏的T细胞相比,缺血衰竭心脏的TCR基因序列呈克隆性扩展,但TRBV-J重排和V基因片段的使用模式相似。与外周血T细胞相比,缺血衰竭心脏中的T细胞具有限制性和克隆性扩张的TCR序列,TRBV-J

心肌梗死引起的持续性心脏T细胞反应与随后的不良心室重塑和心力衰竭进展有关,目前尚无T细胞受体(TCR)剧集的变化与缺血心力衰竭心脏T细胞表型特征结合的数据。

通过高通量测序对TCR基因序列的分析发现,与对照心脏的T细胞相比,缺血衰竭心脏的TCR基因序列呈克隆性扩展,但TRBV-J重排和V基因片段的使用模式相似。与外周血T细胞相比,缺血衰竭心脏中的T细胞具有限制性和克隆性扩张的TCR序列,TRBV-J重排和V基因片段的使用模式存在差异,提示缺血衰竭心脏中存在组织特异性T细胞扩增。TCR克隆型共享在缺血衰竭的心脏中非常突出,特别是在共享人类白细胞抗原(HLA)等位基因的患者的心脏中。此外,缺血性心力衰竭(IHF)患者外周血中心脏相关克隆型的发生率高于对照组。Th1细胞是CD4+T细胞中的主要表型,CD8+T细胞与CD4+T细胞一样丰富,并产生高水平的干扰素γ、颗粒酶B和穿孔素。

研究结果显示,在缺血性人类心脏中,组织特异性T细胞反应主要由Th1细胞和细胞毒性CD8+T细胞组成,可能有助于心力衰竭的进展。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893246, encodeId=631f1893246fb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Feb 26 05:58:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649528, encodeId=00891649528e4, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sun Oct 25 20:58:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357351, encodeId=e02b135e35198, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535250, encodeId=ed29153525078, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563198, encodeId=8e4215631984a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893246, encodeId=631f1893246fb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Feb 26 05:58:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649528, encodeId=00891649528e4, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sun Oct 25 20:58:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357351, encodeId=e02b135e35198, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535250, encodeId=ed29153525078, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563198, encodeId=8e4215631984a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893246, encodeId=631f1893246fb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Feb 26 05:58:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649528, encodeId=00891649528e4, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sun Oct 25 20:58:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357351, encodeId=e02b135e35198, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535250, encodeId=ed29153525078, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563198, encodeId=8e4215631984a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
    2020-01-02 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893246, encodeId=631f1893246fb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Feb 26 05:58:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649528, encodeId=00891649528e4, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sun Oct 25 20:58:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357351, encodeId=e02b135e35198, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535250, encodeId=ed29153525078, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563198, encodeId=8e4215631984a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
    2020-01-02 tastas
  5. [GetPortalCommentsPageByObjectIdResponse(id=1893246, encodeId=631f1893246fb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Feb 26 05:58:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649528, encodeId=00891649528e4, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sun Oct 25 20:58:00 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357351, encodeId=e02b135e35198, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535250, encodeId=ed29153525078, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563198, encodeId=8e4215631984a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 01:58:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
    2020-01-02 slcumt

相关资讯

Heart:男性与更大的胸主动脉直径呈独立相关

本研究的目的旨在提供55岁或55岁以上男性和女性胸主动脉直径的人群分布,并确定胸主动脉直径的决定因素。本研究纳入了2003-2006年2505名(1208名男性,平均年龄69.1±6.8岁)接受了非增强心脏CT检测的参与者,并在肺分叉水平对升主动脉(AA)和降主动脉(DA)的直径进行了测量。分析结果显示,男性的AA和DA直径明显大于女性,男性是更大的DA直径的独立相关因素(β 0.24, 95%

Heart:孤单与心脏病患者不良预后明显相关!

本研究的目的旨在评估孤单是否与缺血性心脏病、心律失常、心衰或心脏瓣膜疾病患者出院后的预后相关。本研究纳入分析了13443名缺血性心脏病、心律失常、心衰或心脏瓣膜疾病患者,并完成了调查随访,其中男性占70%,女性平均年龄是66.1岁,男性的平均年龄是64.9岁。分析结果显示,在不同的疾病种类中,孤单均与更差的预后相关,不论男性和女性。孤单可以预测患者的全因死亡率(男性:HR 2.92,95% CI

Eur Heart J:癌症患者的心血管疾病风险明显更高

本次观察性研究的目的旨在评估多个癌症中心患者的心血管疾病(CVD)死亡风险。本研究对正常人群和3234256名美国癌症幸存者(1973-2012年)进行了监测、流行病学和最终结果的比较。在28个癌症种类患者中,有1228328名患者(38%)死于癌症,365689名患者(11.3%)死于CVD。在死于CVD的患者中,有76.3%的患者是死于心脏病。在八个癌症中心,心血管疾病的死亡率风险在至少一个日

Eur Heart J:慢性系统性炎症是癌症的危险因素

血浆高敏C反应蛋白(CRP)的升高代表的低水平炎症反应是心血管疾病(CVD)的危险因素之一,同样也可能增加癌症的发表风险。本研究的目的旨在评估稳定性CVD患者低水平系统系炎症与癌症发生的相关性。本研究纳入分析了7178名稳定性CVD且血浆CRP≤10mg/L的患者,经过平均8.3年时间的随访,有1072名患者诊断为癌症,CRP水平与总体癌症发生率相关(HR 1.35; 95% CI 1.10-1.

Heart:心包脂肪含量与HIV患者不良的心功能相关

艾滋病毒携带者(PLHIV)改变了脂肪分布,增加了心力衰竭的风险,在这个人群中,心脏周围脂肪的数量和放射密度的改变是否与心功能不全有关尚不清楚。本研究的目的旨在评估HIV患者的心包脂肪(PCF)与心脏功能的相关性。本研究纳入分析了100例年龄>45岁且存在>1个传统心血管危险因素的HIV患者和100年龄和性别匹配的对照。与对照相比,PLHIV患者的BMI更低(27 vs 30, p=0.02),糖

Eur Heart J:预测早期乳腺癌患者心血管风险的评分体系

本研究的目的旨在开发一个评分来预测早期乳腺癌(EBC)后主要心血管事件(MACE)的风险,以促进潜在的心脏毒性治疗和干预以减少心血管风险的个性化决策。本研究纳入了2003-2014年被诊断为EBC的患者,其中三分之二患者用于风险评分的推导;其余的用于验证,主要终点事件是急性心梗、不稳定性心绞痛、短暂性缺血发作、中风、周围血管疾病、心力衰竭或心血管死亡的复合事件。最终,有60294名EBC患者用于风